Table 2: Histological, virologic, serologic, and biochemical response at week 52.

End pointsTreatment group ( )Control group ( ) value

Necroinflammatory improvement*22 (53.7)13 (33.3)0.076
Fibrosis improvement*17 (41.5)14 (35.9)0.652
HBV DNA <1000 copies/mL by PCR assay93 (68.4)91 (67.4)0.897
≥2 lg copies/mL reduction in HBV DNA compared to baseline134 (98.5)125 (92.6)0.019
Mean change in HBV DNA from baseline by PCR assay (lg copies/mL) 0.010
HBeAg loss31 (22.8)17 (12.6)0.038
Undetectable HBV DNA and HBeAg loss29 (21.3)12 (8.9)0.006
HBeAg seroconversion19 (14.0)15 (11.1)0.583
Undetectable HBV DNA and HBeAg seroconversion19 (14.0)11 (8.1)0.175
HBsAg loss2 (1.5)1 (0.7)1.000
ALT normalization106 (77.9)106 (78.5)1.000

A total of 80 patients had adequate baseline and liver-biopsy specimens at week 52 (41 patients in treatment group and 39 in control group). Values in parentheses are percentages unless indicated otherwise; value was presented as mean ± standard deviation.